Literature DB >> 9484806

Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas.

J F Marshall1, D C Rutherford, L Happerfield, A Hanby, A C McCartney, J Newton-Bishop, I R Hart.   

Abstract

Changes in integrin expression have been shown to be important for the growth and metastatic capacity of melanoma cells. In this study, we have examined the expression of alphav integrins by three uveal and four cutaneous malanoma lines. No lines expressed alphavbeta6 and only TXM13, a cutaneous line, expressed alphavbeta8. All lines expressed alphavbeta5 and alphavbeta3 (four out of four cutaneous, two out of three uveal) or avpl (OM431, an uveal line). Thus, OM431 is the second uveal melanoma we have described that expresses alphavbeta1 and this, we report again, functions as an alternative vitronectin/fibronectin receptor. Subcutaneous growth of cell lines in athymic mice correlated with an alphavbeta3-positive, alphavbeta1 -negative phenotype. Analysis of clinical material from cutaneous melanoma showed that although alphav expression was increased in 88% of metastases, this could not all be explained by up-regulation of alphavbeta3, with only 2 out of eight skin metastases expressing this heterodimer. Using antibody SZ.21, which as we report here works in archival material, only 1 out of 15 uveal metastases expressed detectable beta3. Thus, acquisition of alphavbeta3 expression, which has been implicated in cutaneous melanoma progression, may not be required for development of metastases from uveal melanoma or indeed for skin, as distinct from lymph node, metastases of cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484806      PMCID: PMC2149935          DOI: 10.1038/bjc.1998.85

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours.

Authors:  D Schadendorf; C Gawlik; U Haney; H Ostmeier; L Suter; B M Czarnetzki
Journal:  J Pathol       Date:  1993-08       Impact factor: 7.996

2.  Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.

Authors:  J Nip; H Shibata; D J Loskutoff; D A Cheresh; P Brodt
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

3.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.

Authors:  Y Fradet; C Cordon-Cardo; T Thomson; M E Daly; W F Whitmore; K O Lloyd; M R Melamed; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

5.  A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; M Bailly; J F Doré; L L Leung; J L McGregor
Journal:  Blood       Date:  1989-08-15       Impact factor: 22.113

6.  Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice.

Authors:  E H Danen; K F Jansen; A A Van Kraats; I M Cornelissen; D J Ruiter; G N Van Muijen
Journal:  Int J Cancer       Date:  1995-05-16       Impact factor: 7.396

Review 7.  Integrin expression in malignant melanoma.

Authors:  R H Kramer; M Vu; Y F Cheng; D M Ramos
Journal:  Cancer Metastasis Rev       Date:  1991-05       Impact factor: 9.264

8.  The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor.

Authors:  J Davies; J Warwick; N Totty; R Philp; M Helfrich; M Horton
Journal:  J Cell Biol       Date:  1989-10       Impact factor: 10.539

9.  Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.

Authors:  E A Wayner; A Garcia-Pardo; M J Humphries; J A McDonald; W G Carter
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

10.  An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice.

Authors:  F Mitjans; D Sander; J Adán; A Sutter; J M Martinez; C S Jäggle; J M Moyano; H G Kreysch; J Piulats; S L Goodman
Journal:  J Cell Sci       Date:  1995-08       Impact factor: 5.285

View more
  7 in total

1.  A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins.

Authors:  S R Elshaw; K Sisley; N Cross; A K Murray; S M MacNeil; M Wagner; C E Nichols; I G Rennie
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis.

Authors:  Maureen Pickarski; Alexa Gleason; Bohumil Bednar; Le T Duong
Journal:  Oncol Rep       Date:  2015-04-09       Impact factor: 3.906

3.  Effects of Zeaxanthin on Growth and Invasion of Human Uveal Melanoma in Nude Mouse Model.

Authors:  Xiaoliang L Xu; Dan-Ning Hu; Codrin Iacob; Adrienne Jordan; Sandipkumar Gandhi; Dennis L Gierhart; Richard Rosen
Journal:  J Ophthalmol       Date:  2015-11-22       Impact factor: 1.909

4.  Beta1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility.

Authors:  Małgorzata Przybyło; Ewa Pocheć; Paweł Link-Lenczowski; Anna Lityńska
Journal:  Mol Vis       Date:  2008-03-26       Impact factor: 2.367

5.  TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes.

Authors:  E Katerinaki; G S Evans; P C Lorigan; S MacNeil
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

6.  RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells.

Authors:  Domenica Capasso; Ivan de Paola; Annamaria Liguoro; Annarita Del Gatto; Sonia Di Gaetano; Daniela Guarnieri; Michele Saviano; Laura Zaccaro
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

Review 7.  Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment.

Authors:  Marie Luise Semmler; Sander Bekeschus; Mirijam Schäfer; Thoralf Bernhardt; Tobias Fischer; Katharina Witzke; Christian Seebauer; Henrike Rebl; Eberhard Grambow; Brigitte Vollmar; J Barbara Nebe; Hans-Robert Metelmann; Thomas von Woedtke; Steffen Emmert; Lars Boeckmann
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.